Axa S.A. Adverum Biotechnologies, Inc. Transaction History

Axa S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$5.1 - $11.89 $893,790 - $2.08 Million	-175,253 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$3.03 - $6.02 $18,786 - $37,324	6,200 Added 3.67%	175,253 $918,000
Q3 2018 Nov 08, 2018	BUY	$4.5 - $7.6 $21,420 - $36,176	4,760 Added 2.9%	169,053 $1.02 Million
Q2 2018 Aug 13, 2018	BUY	$5.3 - $6.9 $659,812 - $859,001	124,493 Added 312.8%	164,293 $871,000
Q1 2018 May 14, 2018	BUY	$3.65 - $7.95 $145,270 - $316,410	39,800 New	39,800 $231,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $612M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.